Federated Hermes’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Federated Hermes’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-607,687	Closed	-$1M	–	2359
2022 Q1	$1M	Buy	607,687 +1,484	+0.2%	+$2.65K	﹤0.01%	1247
2021 Q4	$1.45M	Sell	606,203 -218,797	-27%	-$891K	﹤0.01%	1141
2021 Q3	$4.5M	Hold	825,000	–	–	0.01%	848
2021 Q2	$6.14M	Hold	825,000	–	–	0.01%	787
2021 Q1	$6.68M	Buy	825,000 +325,000	+65%	+$3.54M	0.01%	768
2020 Q4	$4.55M	Hold	500,000	–	–	0.01%	828
2020 Q3	$5.54M	Hold	500,000	–	–	0.01%	709
2020 Q2	$3.71M	Buy	+500,000	New	+$3.35M	0.01%	795

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Federated Hermes's KLDO Position: Q2 2022 in Review

Federated Hermes sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 607,687 shares — an estimated $1M sold.

Federated Hermes first reported a position in KLDO in Q2 2020 and held it in 8 quarters. The position peaked at $6.68M in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Federated Hermes reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 607,687 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1M.
Federated Hermes first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Federated Hermes's Kaleido Biosciences, Inc. Common Stock position peaked at $6.68M in Q1 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.